posted 08-08-2017 06:37 PM                  

It’s the second time this year the federal government has proposed giving exclusive rights for taxpayer-funded research to a foreign pharmaceutical giant.

The federal government plans to give the exclusive license for a new liver cancer drug to a pharmaceutical company owned by China’s 63rd-richest man, HuffPost has learned.

The National Institutes of Health proposes to grant Salubris Biotherapeutics, Inc. exclusive worldwide rights to a portfolio of patents on antibody drugs used to treat liver cancer, according to a notice published Monday on the Federal Register.

The firm is the Maryland-based arm of Shenzhen Salubris Pharmaceuticals Co., Ltd., the Chinese drugmaker valued at roughly $5 billion and run by former Shenzhen mayor and billionaire Ye Chenghai, who with his family controls about 66 percent of the company.

The proposal comes amid growing public backlash to deals that give pharmaceutical companies monopolies on drugs and vaccines developed through taxpayer-funded research without requiring them to sell the drugs back to Americans at a reasonable price.

Rest of the story: